| 66 | 0 | 81 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 观察非奈利酮联合沙库巴曲缬沙坦及达格列净口服治疗早期糖尿病肾病的临床效果。方法 选取早期2型糖尿病肾病患者68例为研究对象。在年龄、性别等基线资料组间均衡可比的原则下，分为对照组33例、试验组35例。对照组给予沙库巴曲缬沙坦及达格列净治疗，试验组在对照组基础上给予非奈利酮治疗，共治疗12个月。对比两组治疗前后的肾功能指标[血肌酐（Cr）、尿素氮（BUN）、估计肾小球滤过率（eGFR）、尿酸（UA）、尿微量白蛋白（MALB）、尿微量白蛋白/尿肌酐（ACR）]、血糖指标[空腹血糖（FPG）、糖化血红蛋白（HbA1c）]、血压指标[收缩压（SBP）、舒张压（DBP）]、血钾和炎症相关指标[白细胞计数（WBC）、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)]，记录并比较两组不良反应发生情况（如头痛头晕、恶心呕吐、高钾血症、低血压等）。结果 两组治疗后BUN、MALB、ACR、HbA1c、FPG、SBP、DBP、WBC、IL-6、TNF-α均较治疗前降低（P均<0.05）。试验组治疗12个月的Cr水平低于对照组，治疗12个月的eGFR、血钾高于对照组，治疗6、12个月的BUN、MALB、ACR低于对照组，治疗3、6、12个月的WBC、IL-6、TNF-α、SBP低于对照组（P均<0.05）。两组头痛头晕、恶心呕吐、高钾血症、低血压发生率差异无统计学意义（P均>0.05）。结论 非奈利酮联合沙库巴曲缬沙坦及达格列净口服治疗早期糖尿病肾病能够有效减少尿蛋白、改善肾功能、控制血糖和炎症反应，且有助于长期血压管理，但非奈利酮应用过程中有升高血钾的风险，需定期检测血钾水平。
Abstract：Objective To explore the clinical effects of oral treatment with finerenone combined with sacubitril/valsartan and dapagliflozin on early diabetic kidney disease. Methods Sixty-eight patients with early type 2 diabetic nephropathy were selected as the study subjects. Under the principle of balanced and comparable baseline data such as age and gender, the subjects were divided into the control group of 33 cases and experimental group of 35 cases. The control group was treated with sacubitril/valsartan and dapagliflozin, while the experimental group was treated with finerenone in addition to the treatment of the control group for a total of 12 months. We compared the renal function indicators [serum creatinine(Cr), blood urea nitrogen(BUN), estimated glomerular filtration rate(eGFR), uric acid(UA), urinary microalbumin(MALB), and urinary microalbumin-to-creatinine ratio(ACR)], blood glucose indicators [fasting blood glucose(FPG) and glycosylated hemoglobin A1c(HbA1c)], blood pressure indicators [systolic blood pressure(SBP) and diastolic blood pressure DBP], blood potassium and inflammation related indicators [white blood cells(WBC), interleukin-6(IL-6), and tumor necrosis factor-α(TNF-α)] before and after treatment between two groups, and recorded and compared the occurrence of adverse reactions(headache, dizziness, nausea, vomiting, hyperkalemia, and hypotension) between the two groups. Results After treatment, BUN, MALB, ACR, HbA1c, FPG, SBP, DBP, WBC, IL-6, and TNF-α in both groups decreased in comparison with those before treatment(all P<0. 05). The Cr level in the experimental group was lower than that in the control group after 12 months of treatment, while eGFR and blood potassium levels were higher than those in the control group after 12 months of treatment. BUN, MALB, and ACR levels were lower than those in the control group after 6 and 12 months of treatment. WBC, IL-6, TNF-α, and SBP levels were lower than those in the control group after 3, 6, and 12 months of treatment(all P<0. 05). There were no statistically significant differences in the incidence of headache, dizziness, nausea and vomiting, hyperkalemia, or hypotension between the two groups(all P>0. 05). Conclusions Oral treatment of early diabetic kidney disease with finerenone combined with sacubitril/valsartan and dapagliflozin can effectively reduce urinary protein, improve renal function, control blood sugar and inflammatory reaction, and help long-term blood pressure management. However, there is a risk of increasing blood potassium during the use of finerenone, and blood potassium levels need to be regularly measured.
[1]ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016,375(9):905-906.
[2]ASSOCIATION A D. Microvascular complications and foot care[J]. Diabetes Care, 2017,40(Suppl 1):S88-S98.
[3]DAVIES M J, D'ALESSIO D A, FRADKIN J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetes Care, 2018,41(12):2669-2701.
[4]ASSOCIATION A D. Microvascular complications and foot care:standards of medical care in diabetes-2020[J]. Diabetes Care,2020,43(Suppl 1):S135-S151.
[5]BARRERA-CHIMAL J, LIMA-POSADA I, BAKRIS G L, et al.Mineralocorticoid receptor antagonists in diabetic kidney diseasemechanistic and therapeutic effects[J]. Nat Rev Nephrol, 2022,18(1):56-70.
[6]万瑾瑾，刁倩，徐菲，等.治疗糖尿病肾病的新型醛固酮受体拮抗剂——非奈利酮[J].医药导报，2022,41(10):1486-1490.
[7]Disease Kidney:Improving Global Outcomes(KDIGO)Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022,102(5S):S1-S127.
[8]中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志，2021,37(3):255-304.
[9]Disease Kidney:Improving Global Outcomes(KDIGO)Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease[J]. Kidney Int, 2021,99(3S):S1-S87.
[10]TOTH-MANIKOWSKI S, ATTA M G. Diabetic kidney disease:pathophysiology and therapeutic targets[J]. J Diabetes Res,2015,2015:697010.
[11]PICHAIWONG W, HUDKINS K L, WIETECHA T, et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy[J]. J Am Soc Nephrol, 2013,24(7):1088-1102.
[12]ROSSING P, CARAMORI M L, CHAN J, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease:an update based on rapidly emerging new evidence[J]. Kidney Int, 2022,102(5):990-999.
[13]GUPTA S, DOMINGUEZ M, GOLESTANEH L. Diabetic kidney disease:an update[J]. Med Clin North Am, 2023,107(4):689-705.
[14]KUANG H, HUANG X, ZHOU Z, et al. Sacubitril/valsartan in chronic kidney disease:From pharmacological mechanism to clinical application[J]. Eur J Pharmacol, 2021,907:174288.
[15]NIU C Y, YANG S F, OU S M, et al. Sacubitril/Valsartan in patients with heart failure and concomitant end-stage kidney disease[J]. J Am Heart Assoc, 2022,11(18):e26407.
[16]KAZE A D, ZHUO M, KIM S C, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease:a meta-analysis[J]. Cardiovasc Diabetol, 2022,21(1):47.
[17]KIM Y K, NING X, MUNIR K M, et al. Emerging drugs for the treatment of diabetic nephropathy[J]. Expert Opin Emerg Drugs,2022,27(4):417-430.
[18]CAI A, SHEN J, YANG X, et al. Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels[J]. Front Immunol, 2023,14:1205834.
[19]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息，2018,31(19):37-39.
[20]VALLON V, VERMA S. Effects of SGLT2 Inhibitors on kidney and cardiovascular function[J]. Annu Rev Physiol, 2021,83:503-528.
[21]EPSTEIN M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal Injury:From hans selye to the present[J]. Am J Nephrol, 2021,52(3):209-216.
[22]LYTVYN Y, GODOY L C, SCHOLTES R A, et al. Mineralocorticoid antagonism and diabetic kidney disease[J]. Curr Diab Rep, 2019,19(1):4.
[23]GOMEZ-SANCHEZ E, GOMEZ-SANCHEZ C E. The multifaceted mineralocorticoid receptor[J]. Compr Physiol, 2014,4(3):965-994.
[24]ERRAEZ S, LOPEZ-MESA M, GOMEZ-FERNANDEZ P. Mineralcorticoid receptor blockers in chronic kidney disease[J]. Nefrologia(Engl Ed), 2021,41(3):258-275.
[25]JIA T, XU T, SMEETS B, et al. The role of platelet-derived growth factor in focal segmental glomerulosclerosis[J]. J Am Soc Nephrol, 2023,34(2):241-257.
[26]GEORIGIANOS P I, AGARWAL R. Resistant hypertension in chronic kidney disease:prevalence, treatment particularities,and research agenda[J]. Curr Hypertens Rep, 2020,22(10):84.
[27]SELVARAJ S, CLAGGETT B, SHAH S J, et al. Utility of the cardiovascular physical examination and impact of spironolactone in heart failure with preserved ejection fraction[J]. Circ Heart Fail, 2019,12(7):e6125.
[28]PITT B, FILIPPATOS G, AGARWAL R, et al. Cardiovascular events with Finerenone in kidney disease and type 2 diabetes[J].N Engl J Med, 2021,385(24):2252-2263.
[29]BAKRIS G L, AGARWAL R, ANKER S D, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020,383(23):2219-2229.
[30]AMAZIT L, LE BILLAN F, KOLKHOF P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1[J]. J Biol Chem, 2015,290(36):21876-21889.
[31]RICO-MESA J S, WHITE A, AHMADIAN-TEHRANI A, et al.Mineralocorticoid receptor antagonists:a comprehensive review of finerenone[J]. Curr Cardiol Rep, 2020,22(11):140.
[32]AGARWAL R, ANKER S D, BAKRIS G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes:the role of finerenone[J]. Nephrol Dial Transplant, 2022,37(6):1014-1023.
[33]司马亮，俞曼殊，盛梅笑.服用非奈利酮对糖尿病肾病患者血清钾水平影响的系统评价[J].山东医药，2024,64(15):41-44.
[34]AGARWAL R, JOSEPH A, ANKER S D, et al. Hyperkalemia risk with finerenone:results from the FIDELIO-DKD trial[J]. J Am Soc Nephrol, 2022,33(1):225-237.
[35]AGARWAL R, KOLKHOF P, BAKRIS G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine[J]. Eur Heart J, 2021,42(2):152-161.
基本信息:
DOI：
中图分类号:R692.9;R587.2
引用信息:
[1]张秋阳,刘金瑞,武相,等.非奈利酮联合沙库巴曲缬沙坦及达格列净治疗早期糖尿病肾病疗效观察[J].山东医药,2025,65(12):1-6.
基金信息:
河南省科技攻关项目（242102311081）